Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHD

April 4, 2023

https://www.globenewswire.com/news-release/2023/04/04/2640421/0/en/Cingulate-Completes-First-Cohort-of-Phase-3-Adult-Onset-and-Duration-Trial-of-CTx-1301-dexmethylphenidate-for-ADHD.html

Trial On Track for 3Q 2023 Results

Pivotal Phase 3 Trial in Pediatric/Adolescent Patients Planned to Begin Mid-2023

KANSAS CITY, Kan., April 04, 2023 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced it has completed the first cohort of its Phase 3 adult onset and duration trial of its lead candidate, CTx-1301 (dexmethylphenidate), for attention deficit/hyperactivity disorder (ADHD).

Read more at globenewswire.com

Related news for (CING)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.